Affordable Access

Access to the full text

ROS1 Targeted Therapies: Current Status

Authors
  • Azelby, Christine M.1
  • Sakamoto, Mandy R.1
  • Bowles, Daniel W.2, 3
  • 1 University of Colorado Anschutz Medical Campus, Colorado, AU, USA , Colorado (United States)
  • 2 University of Colorado Anschutz Medical Campus, 12801 E 17th Ave, 1665 Aurora Court, Colorado, AU, USA , Colorado (United States)
  • 3 Rocky Mountain Regional VA Medical Center, Aurora, CO, USA , Aurora (United States)
Type
Published Article
Journal
Current Oncology Reports
Publisher
Springer-Verlag
Publication Date
Jun 14, 2021
Volume
23
Issue
8
Identifiers
DOI: 10.1007/s11912-021-01078-y
Source
Springer Nature
Keywords
Disciplines
  • Topical Collection on Evolving Therapies
License
Yellow

Abstract

AbstractPurpose of ReviewMolecular drivers are increasingly identified as therapeutic targets for non-small cell lung cancer (NSCLC). This review focuses on the role of ROS1 inhibitors in treating relapsed/metastatic ROS-1 altered (ROS1+) NSCLC.Recent FindingsFour FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib. Each drug yields an overall response rates exceeding 60% with ciritinib, lorlatinib, and entrectinib possessing intracranial activity. The drugs have manageable toxicity profiles.SummaryROS1 alterations are rare molecular drivers of NSCLC that can be effectively treated with a variety of ROS1-targetd drugs. New agents are being identified that may treat resistance mutations.

Report this publication

Statistics

Seen <100 times